Cutaneous Leiomyosarcoma: A SEER Database Analysis.

Area of Science:

• Dermatology
• Oncology
• Pathology

Background:

• Cutaneous leiomyosarcoma (CLS) is a rare dermal neoplasm originating from pilar smooth muscle.
• CLS is often considered indolent, but its behavior requires further clarification due to conflicting literature.
• Debate exists regarding the appropriateness of classifying CLS as a sarcoma.

Purpose of the Study:

• To define the clinical behavior of CLS.
• To characterize the demographic and pathologic features of CLS.
• To compare CLS with aggressive (cutaneous angiosarcoma) and indolent (atypical fibroxanthoma) neoplasms.

Main Methods:

• Utilized the Surveillance, Epidemiology and End Results (SEER) database.
• Collected data on CLS and two reference populations: cutaneous angiosarcoma and atypical fibroxanthoma.
• Analyzed demographic, oncologic characteristics, overall survival (OS), and disease-specific survival (DSS).

Main Results:

• CLS and atypical fibroxanthoma showed lower stage, smaller size, and reduced disease-specific mortality compared to angiosarcoma.
• CLS demonstrated a 5-year disease-specific survival rate of 98% and an OS rate of 85%.
• Atypical fibroxanthoma had a 5-year disease-specific mortality rate of 7.8%.

Conclusions:

• Cutaneous leiomyosarcoma exhibits indolent behavior, comparable to atypical fibroxanthoma.
• CLS should be differentiated from aggressive cutaneous and subcutaneous sarcomas.
• Alternative diagnostic terms, such as "atypical intradermal smooth-muscle neoplasm," may better reflect CLS's biologic potential.